GlassScriptPhysician profile
Errol D Crook
NPI 1235181181
$3,798.36
in general payments reported to CMS, 2019-2025
36 companies · $35.52 in 2025
The $35.52 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $121 · 2021: $664 · 2022: $1,923 · 2023: $15.52 · 2025: $35.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.06 · Education: $4.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.06 |
| Education | $4.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,485.52 | 2022 | |
| Janssen Pharmaceuticals, INC | $321.67 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $232.76 | 2019-2022 | |
| United Therapeutics Corporation | $217.19 | 2019-2021 | |
| Gilead Sciences, INC. | $193.22 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $191.27 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $166.99 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $119.90 | 2019-2020 | |
| Melinta Therapeutics, LLC | $70.42 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $69.29 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.94 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $60.71 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $55.26 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $51.34 | 2021-2022 | |
| Mannkind Corporation | $44.84 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $43.17 | 2019 | |
| Circassia INC. | $31.75 | 2019 | |
| Glaxosmithkline, LLC. | $29.56 | 2019 | |
| Novo Nordisk INC | $28.43 | 2019 | |
| Janssen Biotech, INC. | $27.99 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.75 | 2019 | |
| Vyera Pharmaceuticals, LLC | $27.41 | 2019 | |
| Astellas Pharma US INC | $25.67 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $23.66 | 2022 | |
| Grifols USA, LLC | $21.16 | 2019 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Philips North America LLC | $18.12 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $18.08 | 2022 | |
| Chiesi USA, INC. | $16.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.64 | 2022 | |
| Amgen INC. | $15.52 | 2023 | Repatha |
| Shire North American Group INC | $15.33 | 2019 | |
| Pfizer INC. | $15.01 | 2021 | |
| Mylan Specialty L.P. | $14.75 | 2019 | |
| Corcept Therapeutics | $14.53 | 2021 | |
| Travere Therapeutics, INC. | $4.98 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Errol Crook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.